The emerging sector of specialty pharma—companies building a business around in-licensing poorly penetrated drugs and growing their share through targeted sales efforts—represents an increasing percentage of total dealmaking volume. But could its strategy already be suffering from diminishing returns?
In the chart below, we've broken out average total values of deals in which a specialty pharma was the in-licenser...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?